466P - Gefitinib retreatment beyond progression in advanced NSCLC patients with sensitive EGFR mutations

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer Agents
Non-Small-Cell Lung Cancer, Metastatic
Presenter Lan Sun
Citation Annals of Oncology (2016) 27 (suppl_9): ix139-ix156. 10.1093/annonc/mdw594
Authors L. Sun, L. Tu, M. Wei
  • Oncology, The people's hospital of Bishan District, 402760 - Chongqing/CN



This study was conducted to evaluate the effectiveness and safety of gefitinib retreatment beyond progression in advanced non-small cell lung cancer (NSCLC) patients who had sensitive EGFR mutations.


16 patients with sensitive EGFR mutations in the stage III/IV NSCLC were retrospectively analyzed. Patients were first-line treated with gefitinib. Subseqently disease progression occurred slowly (PFS-1 ≥6 months). According to previous reports, these patients were arranged to receive gefitinib retreatment beyond the first progression. The progression-free survival time (PFS-1) was defined by RECIST version 1.1 and the second-progression-free survival time (PFS-2) was defined as the interval time between the first progression and the second decided by individual's experience. The Kaplan-Meier analysis was performed for PFS and OS. Toxicities were recorded according to the NCI-CTC version 3.0.


16 patients aged 53–80 years (median 66 years). The median follow-up period was 24.0 months. The median PFS-1 and PFS-2 were 10.0 (95% CI: 6.1–13.9 months) and 14.0 (95% CI: 8.8–19.2 months), respectively. The median Overall Survival (OS) time was 36.0 months (95% CI: 17.3–54.7 months). The sex, age, location and genetype subgroup analyses of PFS-1 had no diffrerences as well as PFS-2 and OS. The side effects of gefitinib retreatment were fatigue, diarrhea, rash, itching and elevated transaminases. H owever, grade 3 or 4 toxicity was not observed. There were no treatment-related deaths.


For those advanced NSCLC patients with sensitive EGFR mutations, gefitinib retreatment beyond progression was an effective and endurable treatment.

Clinical trial indentification

Legal entity responsible for the study



Medical research project of Chongqing Municipal Health Bureau (No.20142204)


All authors have declared no conflicts of interest.